Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eledon Pharmaceuticals Inc (NQ: ELDN )

1.250 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.250
Bid (Size) 1.130 (1)
Ask (Size) 1.580 (10)
Prev. Close 1.250
Today's Range 1.250 - 1.250
52wk Range 1.080 - 3.700
Shares Outstanding 22,506,956
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-44.93%
-44.93%
1 Month
-19.35%
-19.35%
3 Month
-8.09%
-8.09%
6 Month
-46.70%
-46.70%
1 Year
-54.55%
-54.55%

More News

Read More
Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Recap: Eledon Pharma Q1 Earnings
Via Benzinga
Eledon Pharma's Earnings: A Preview
Via Benzinga
Eledon Pharmaceuticals's Earnings: A Preview
Via Benzinga
Eledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Why Chewy Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
Eledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.